AU2017342086A1 - Treatment of cholangiocarcinoma with TPCS-2a induced photochemical internalisation of gemcitabine - Google Patents

Treatment of cholangiocarcinoma with TPCS-2a induced photochemical internalisation of gemcitabine Download PDF

Info

Publication number
AU2017342086A1
AU2017342086A1 AU2017342086A AU2017342086A AU2017342086A1 AU 2017342086 A1 AU2017342086 A1 AU 2017342086A1 AU 2017342086 A AU2017342086 A AU 2017342086A AU 2017342086 A AU2017342086 A AU 2017342086A AU 2017342086 A1 AU2017342086 A1 AU 2017342086A1
Authority
AU
Australia
Prior art keywords
gemcitabine
tpcs
cytotoxic agent
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017342086A
Other languages
English (en)
Inventor
Kristin EIVINDVIK
Lena FINNESAND
Anders HØGSET
Pål Kristian SELBO
Per Edvard WALDAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PCI Biotech AS
Original Assignee
PCI Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1617526.7A external-priority patent/GB201617526D0/en
Priority claimed from GBGB1704719.2A external-priority patent/GB201704719D0/en
Application filed by PCI Biotech AS filed Critical PCI Biotech AS
Publication of AU2017342086A1 publication Critical patent/AU2017342086A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017342086A 2016-10-14 2017-10-13 Treatment of cholangiocarcinoma with TPCS-2a induced photochemical internalisation of gemcitabine Abandoned AU2017342086A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1617526.7A GB201617526D0 (en) 2016-10-14 2016-10-14 Method
GB1617526.7 2016-10-14
GB1704719.2 2017-03-24
GBGB1704719.2A GB201704719D0 (en) 2017-03-24 2017-03-24 Method
PCT/EP2017/076257 WO2018069536A1 (en) 2016-10-14 2017-10-13 Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine

Publications (1)

Publication Number Publication Date
AU2017342086A1 true AU2017342086A1 (en) 2019-05-09

Family

ID=60186250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017342086A Abandoned AU2017342086A1 (en) 2016-10-14 2017-10-13 Treatment of cholangiocarcinoma with TPCS-2a induced photochemical internalisation of gemcitabine

Country Status (13)

Country Link
US (1) US20200338044A1 (enExample)
EP (1) EP3525783B1 (enExample)
JP (1) JP2019530718A (enExample)
KR (1) KR20190068573A (enExample)
CN (1) CN110022874A (enExample)
AU (1) AU2017342086A1 (enExample)
CA (1) CA3040344A1 (enExample)
DK (1) DK3525783T3 (enExample)
ES (1) ES2841941T3 (enExample)
PL (1) PL3525783T3 (enExample)
RU (1) RU2019109682A (enExample)
SG (1) SG11201903057XA (enExample)
WO (1) WO2018069536A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913124D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
CN100558903C (zh) 2000-11-29 2009-11-11 Pci生物技术联合股份有限公司 将分子输递进胞质溶胶的光化学内化法
GB0121023D0 (en) * 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method

Also Published As

Publication number Publication date
EP3525783A1 (en) 2019-08-21
DK3525783T3 (da) 2021-01-18
SG11201903057XA (en) 2019-05-30
US20200338044A1 (en) 2020-10-29
ES2841941T3 (es) 2021-07-12
JP2019530718A (ja) 2019-10-24
PL3525783T3 (pl) 2021-04-19
KR20190068573A (ko) 2019-06-18
RU2019109682A3 (enExample) 2021-02-15
CA3040344A1 (en) 2018-04-19
CN110022874A (zh) 2019-07-16
EP3525783B1 (en) 2020-12-16
WO2018069536A1 (en) 2018-04-19
RU2019109682A (ru) 2020-11-16

Similar Documents

Publication Publication Date Title
Spring et al. The role of photodynamic therapy in overcoming cancer drug resistance
Bisland et al. Metronomic Photodynamic Therapy as a New Paradigm for Photodynamic Therapy: Rationale and Preclinical Evaluation of Technical Feasibility for Treating Malignant Brain Tumors¶
Berg et al. Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin
Aebisher et al. The use of photodynamic therapy in medical practice
Crescenzi et al. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
Ogata et al. Near-infrared photoimmunotherapy: a comparison of light dosing schedules
TW200902114A (en) Methods and systems for treating cell proliferation disorders
TW200914054A (en) Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
Spring et al. Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck
EP3525783B1 (en) Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine
AU2016206832A1 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
CN111343984A (zh) 包含链黑菌素及雷帕霉素作为有效成分的癌症预防或治疗用药学组合物
Sellers et al. From conventional to cutting edge: An exploration of osteosarcoma treatments
Fiveash et al. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5
Sun et al. Light dose effect of photodynamic therapy on growth inhibition and apoptosis induction in non-small cell lung cancer: A study in nude mouse model
US20210283255A1 (en) Reducing Damage From Chemotherapy And Increasing Cancer Kill Rates By Using Interweaved Low Dose Radiation
Yang et al. Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study
Wirth et al. Strategies to improve drug delivery in bladder cancer therapy
Murphy et al. Gemcitabine-mediated radiosensitization of human soft tissue sarcoma
RU2524309C1 (ru) Способ выбора тактики лечения местно-распространенного рака предстательной железы
Goujani et al. Comparative analysis of combined methylene blue photodynamic therapy and doxorubicin treatment of oral squamous cell carcinoma cell line: In vitro study on apoptosis
Biel Clinical photodynamic therapy: The evolution of photodynamic therapy treatment of head and neck cancer
TWI434829B (zh) 以密環菌乙素來治療癌症之新穎用途
Magné et al. Concomitant chemo-radiotherapy in clinical trials: To promote step by step rational development
園川卓海 et al. Development of a new minimally invasive phototherapy for lung cancer using antibody-toxin conjugate

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application